Skip to main content
Diseases of the Esophagus logoLink to Diseases of the Esophagus
. 2021 Aug 10;34(11):doab054. doi: 10.1093/dote/doab054

Long-term neurodevelopment in children born with esophageal atresia: a systematic review

Camille E van Hoorn 1,2,, Chantal A ten Kate 3, Andre B Rietman 4, Leontien C C Toussaint-Duyster 5, Robert Jan Stolker 6, Rene M H Wijnen 7, Jurgen C de Graaff 8
PMCID: PMC8597907  PMID: 34378009

Summary

Background

Although the survival rate of esophageal atresia (EA) has increased to over 90%, the risk of functional long-term neurodevelopmental deficits is uncertain. Studies on long-term outcomes of children with EA show conflicting results. Therefore, we provide an overview of the current knowledge on the long-term neurodevelopmental outcome of children with EA.

Methods

We performed a structured literature search in Embase, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google scholar on November 8, 2020 with the keywords ‘esophageal atresia’, ‘long-term outcome’, ‘motor development’, ‘cognitive development’, and ‘neurodevelopment’.

Results

The initial search identified 945 studies, of which 15 were included. Five of these published outcomes of multiple tests or tested at multiple ages. Regarding infants, one of six studies found impaired neurodevelopment at 1 year of age. Regarding preschoolers, two of five studies found impaired neurodevelopment; the one study assessing cognitive development found normal cognitive outcome. Both studies on motor function reported impairment. Regarding school-agers, the one study on neurodevelopmental outcome reported impairment. Cognitive impairment was found in two out of four studies, and motor function was impaired in both studies studying motor function.

Conclusions

Long-term neurodevelopment of children born with EA has been assessed with various instruments, with contrasting results. Impairments were mostly found in motor function, but also in cognitive performance. Generally, the long-term outcome of these children is reason for concern. Structured, multidisciplinary long-term follow-up programs for children born with EA would allow to timely detect neurodevelopmental impairments and to intervene, if necessary.

Keywords: children, esophageal atresia, neurology

INTRODUCTION

Esophageal atresia (EA) is a congenital deformity in which the upper esophagus does not connect to the lower esophagus and the stomach, which occurs in 2.43 per 10,000 live births.1 After correction of the defect, >90% of the children born with EA survive nowadays.2 Therefore, long-term outcome requires growing attention. The evaluation of long-term outcome in children born with EA focuses on several aspects, such as gastroesophageal reflux, dysphagia, respiratory problems, weight, growth, quality of life (QOL), psychological status, social behavior, and neurodevelopment.2–4

Most research on long-term outcome of EA has focused on physical impairments or QOL, both in children and young adults.5,6 A recent elaborate review on health related QOL (HrQOL) of patients born with EA concluded that clinical subgroups of children with EA present with impaired HrQOL, and that digestive symptomology negatively influences the HrQOL.6 Neurodevelopment has been less well studied, and available studies reported conflicting results. Furthermore, the variety of used test instruments and cohorts make it difficult for clinicians to interpret these results, and a comparative study is lacking.

More research on neurodevelopmental outcome has been performed in neonates with other conditions. After extracorporeal membrane oxygenation (ECMO) treatment, 10–50% of children showed cognitive impairment of >2 standard deviation (SD), and motor impairment was found in 12%.7 In children born with diaphragmatic hernia, significantly more problems with motor function, concentration, and behavioral attention were found, compared with reference groups. Intelligence quotient (IQ) levels were lower for those who had received ECMO treatment.8,9

The risk factors children born with EA are exposed to are similar to the risk factors patients with congenital diaphragmatic hernia and/or ECMO face. This includes, amongst others, neonatal surgery, metabolic derangements during surgery, admission to the intensive care unit, and endotracheal intubation.9,10 Therefore, it cannot be ruled out that patients born with EA suffer comparable neurodevelopmental impairments as these patient populations do.

Neurodevelopment is the brain’s ability to develop neurological pathways facilitating performance in daily life. These pathways support the functioning of the brain, including motor function (e.g. agility and balance) and cognitive performance (e.g. think, learn, and remember). Motor function and cognitive performance are strongly interrelated and interdependent, displaying marked parallels, and multiple points of connection in the brain.11 Therefore, these factors cannot be seen as separate factors and are always impacted by the other and integrated in a test.

Better insight in long-term neurodevelopmental outcome is important for healthcare professionals as well as for children with EA and their parents, and will be helpful to guide future counselling, follow-up, and treatment. In this systematic review we therefore aim to inventory the current knowledge on long-term neurodevelopmental outcome—including cognitive and motor functioning—in children who underwent primary surgery for EA.

METHODS

A broad systematic literature search was performed to identify clinical research on long-term neurodevelopment in children born with EA, following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.12 A structured electronic search was performed on November 8th, 2020 in the EMBASE, MEDLINE, Web of Science, COCHRANE, and Google scholar databases.13 The search terms were the following: “esophageal atresia’, ‘long-term outcome’, ‘motor development’, ‘cognitive development’, and ‘neurodevelopment’ (complete search strategy is provided in Supplementary Material). Limits were set to English language and human studies. This systematic review was registered in the PROSPERO database (registration number CRD42020203189).

After deduplication of the retrieved citations in Endnote,14 the titles and abstracts of the remaining studies were screened by two investigators (CvH and CtK), independently and in a systematic fashion. The inclusion criteria were: studies in children born with EA between 6 months and 18 years of age, with long-term neurodevelopment (either motor function and/or cognitive functioning) as primary outcome. Studies including children younger than 6 months old were excluded, since these were considered to describe the short-term effects of surgery and anesthesia. Neurodevelopment had to be assessed by means of neuropsychological evaluation or a validated questionnaire to assess neurodevelopment. Studies that focused only on QOL, psychological development, respiratory complications, or physical comorbidities were excluded. These types of studies were excluded because clinical presentation of patients EA is very heterogenic, which makes it hard to compare outcome variables. Last, studies not originally published in a peer-reviewed journal were excluded.

The remaining studies were selected for full-text analysis. Both investigators (CvH and CtK) independently read the full-texts of these citations. Discrepancies were solved through discussion, or by mediation from a third investigator (JdG), which resulted in the final selection.

The following data were extracted: number of patients, age, outcome measure (motor or cognitive functioning), test method, and test results. As various age-dependent tests are available to assess neurodevelopment in children, we report the search results for three age groups: infants <2 years old, preschoolers aged 2–5 years old, and school-aged children of 6–18 years old. This division is based on the age groups used for assessing neurodevelopment in children, based on developmental stages.15

Risk of bias was analyzed using the methodological index for non-randomized studies (MINORS).16 Due to small amount of included studies and the heterogeneity of the data provided by the included studies, we were not able to perform a meta-analysis of the data.

RESULTS

The search strategy yielded 1774 citations, of which 945 studies remained after deduplication. Based on the predetermined exclusion criteria, 908 studies were excluded after initial screening of title and abstract. Of the remaining 37 studies selected for full-text analysis, 22 studies were excluded (Fig. 1). We found 9 studies in which questionnaires were used to assess neurodevelopment of the patients. These studies did not use validated questionnaires and were therefore not included in this systematic review. Only one study used the ages and stages questionnaire (ASQ) to screen patients for patients to be tested with Bayley-3 (see further).17 Four studies were published as conference abstract or as a review only, and two reported on a subgroup of another study.18,19 Four other studies combined multiple congenital anomalies without specifying the test results for the patients with EA. One article was not written in English, and another article was excluded as we had no access to the full-text. One article was excluded due to an inclusion bias; development was only evaluated when a developmental disorder was already suspected.

Fig. 1.

Fig. 1

Inclusion flowchart.

Ultimately, 15 studies were included in this systematic literature review, with a large variation of tests and age groups. Some studies investigated neurodevelopment of the study group at various ages (Table 1 and Fig. 2).

Table 1.

Baseline characteristics of included studies (n = 15)

Author, year Type of study Operated/born/tested Age tests Tests Reference population No. of patients included* Mortality (n) No. at follow-up Type of EA Gestational age (weeks) birth weight Comorbidities
Bouman27
Netherlands, 1999
Prospective cohort study NR 8–12 years WISC-RN Dutch references 36 NR 36 Isolated EA n = 5
EA with TEF n = 31
NR
NR
NR
Faugli36
Norway, 2009
Prospective cohort study Born 1999–2002 1 year BSID-II US references 44 2 39 (36) 10% delayed repair 23% born <37 weeks
2830 (595–4570)A
20% ≥1 associated anomaly (tetralogy of Fallot, biliary atresia, anorectal malformation, tracheomalacia)
Gischler36
Netherlands, 2009
Prospective longitudinal cohort study Tested 1999–2003 6, 12, 18, and 24 months BSID-I/II** Dutch references 17 NR 13 NR 38.6 (36.9–40.1)B
3000 (2600–3200)B
Syndromal/chromosomal n = 1, severe neurologic impairment n = 2, major congenital anomalies n = 1#
Van der Cammen-van Zijp25
Netherlands, 2010
Prospective cohort study Born 1999–2003 5 years MABC Dutch references 29 NR 29 NR 38.4 (28.6–42.0)A
2900 (800–4500)
31% ≥1 associated anomaly
Kubota29
Japan, 2011
Prospective cohort study NR 6–17 years WISC-3
KSPD
Japanese references 23 NR 23 NR NR
NR
NR
Walker35
Australia, 2013
Prospective case–control study Operated Aug 2006–Dec 2008 1 year Bayley-3 Study control group 34 1 31 NR 37.6C
2718 ± 717D
44% ≥1 associated anomaly
Francesca34
Italy, 2020
Observational prospective cohort study Born 2009–2017 6 and 12 months Bayley-3 Age-normed 90 NR 82
59
Type C and D 38 (37–39)B
2700 (2450–3030)
NR
Bakal20
Turkey, 2016
Cross-sectional study Operated Jan 1996–Dec 2011 6–16 years ADSI
WISC-R
Turkish references 57 18 24 ADSI
15 WISC-R
Type A n = 6
Type C n = 50
Type E n = 1
40% born <37 weeks
2255.26 ± 600.27D
35% ≥1 associated anomaly
Giúdici23
Argentina, 2016
Prospective cohort study Born Jan 2003–Dec 2014 1, 3, and 6 years CAT/
CLAMS
PRUNAPE
Argentinian references 23 4 21 at 1 year
14 at 3 years
10 at 6 years
Type A n = 3
Type C n = 20
38.3 ± 1.6D
2917 ± 440D
Trisomy 21 n = 1, Edwards syndrome n = 1
Walker26
Australia, 2016
Prospective case–control study Operated Aug 2006–Dec 2008 3 years Bayley-3 Study control group 31 0 24 NR 38C
2765C
NR
Harmsen24
Netherlands, 2017
Prospective cohort study Born Jan 1999–May 2006 5 and 8 years MABC I/II
WISC-3-NL
RAKIT
Dutch references 78 7 54 motor
49 cognitive
91% type C 39 (29–42)A
2830 (750–4505)A
12% cardiac anomaly, 5% VACTERL association
König28
Germany, 2018
Cross-sectional study NR 3–12 years Deutscher Motorik Test German references 17 NR 12 NR 54% born <37 weeks
23% <1500 grams
46% congenital heart disease, 38% developmental delay, 28% skeletal deformity, 15% anorectal malformation
Mawlana17
Canada, 2018
Retrospective chart review Operated Jan 2000–Dec 2015 2–3 years Bayley-3 US references 253 21 182 Type A n = 13
Type B n = 2
Type C n = 149
Type D n = 4
Type E n = 14
36.8 ± 3.2D
2589 ± 800D
NR
Costerus21
Netherlands, 2019
Prospective cohort study Operated Aug 2011–Aug 2013 1 and 2 years BSID-II Dutch references 6 NR 5 NR 39.0 (34.0–40.0)A
2850 (1941–3338)A
Tetralogy of Fallot n = 1, kidney dysplasia n = 1, Feingold syndrome n = 1, intestinal malrotation n = 1
Batta37
Australia, 2020
Retrospective study Born 2005–2014 1 year GMDS-II General population references 44 1 27 NR 37.6 (36.4–39.1)B
3000 (2590–3405)B
NR

EA, esophageal atresia; NR, not reported; TEF, tracheoesophageal fistula. Type of EA according to gross classification.54 VACTERL, vertebral, anorectal, tracheoesophageal, renal, or limb defects55

AMedian (range).

BMedian (IQR).

CMean.

DMean ± SD.

#

These four patients were excluded from neurodevelopmental assessment.

*Included in neurodevelopmental assessment.

**Dutch version of the BISD I/II: BOS 2-30.

Fig. 2.

Fig. 2

(A). Outcome scores cognitive performance. Each line represents cognitive performance (mean [SD]) per study at the specified age in month (m). The dot represents the mean test result, the line represents the SD. Studies from which no crude test scores could be obtained are not included in this graph. *95% CI reported instead of mean (SD). The normal score ranges from 85 to 115, displayed by the lines at 85 and 115. (B) Outcome scores motor function. Each line represents motor outcome (mean [SD]) per study. The dot represents the mean test result, the line represents the SD at the specified age group in months (m). *95% CI reported instead of mean (SD). The normal score ranges from 85 to 115, displayed by the lines at 85 and 115. Outcome data from van der Cammen-van Zijp and Harmsen could not be included in this graph due to their reported outcome measures lacking mean (SD) data.

Neurodevelopmental outcome was described for infants (<2 years old) in six studies, for preschoolers (2–5 years old) in eight studies,17,20–26 and for school-aged children (>6 years old) in six studies20,23,24,27–29 (Tables 24). The sample size ranged from 6 to 182 children; the children’s ages ranged from 6 months to 17 years old. A total of 769 tests were conducted, in which the Bayley Scales of Infant and Toddler Development (BSID-I, BSID-II, and Bayley-3), the Movement assessment battery for children (M-ABC) and the Wechsler Intelligence Scale for Children (WISC) were most frequently used. BSID has been internationally validated for children up to 42 months old; the most recent version measures five domains of development, including motor skills and cognition.30 To measure motor skills of children aged 4 up to and including 16 years old, the M-ABC has been developed and validated internationally.31,32 For cognitive performance, the WISC is available for children from 6 to 16 years old.33

Table 2.

Neurodevelopmental outcome in infants (<2 years old) born with esophageal atresia

Age (months) Author, year No. of patients ( n ) Test method Outcome measure Test result Conclusion
6 Gischler*22
Netherlands, 2009
13 BSID-I Motor 98.5 (89.3–107.7)A Normal
Cognition 91.5 (79.0–104.0)
Francesca34
Italy, 2020
82 Bayley-3 Motor 98.4 ± 12.8B Normal
Cognition 93.9 ± 10.4
12 Gischler22
Netherlands, 2009
13 BSID-I Motor 98.8 (86.8–110.8)A Normal
Cognition 97.2 (77.0–117.5)
Faugli36
Norway, 2009
36 BSID-II Motor 97 (56–121)C Normal
Cognition 103 (71–118)
Walker35
Australia, 2013
31 Bayley-3 Fine motor 9.16D Expressive language impaired (P < 0.05), other scales normal
Gross motor 8.37
Cognition 11.00
Receptive language 10.23
Expressive language 9.03
Francesca34
Italy, 2020
59 Bayley-3 Motor 93.4 ± 10.3B Normal
Cognition 103.3 ± 9.1
Giúdici23
Argentina, 2016
21 CAT/CLAMS Visomotor & receptive and expressive language skills Normal in n = 16 (76%)
Abnormal n = 5 (24%)
Significantly lower than normal
Batta37
Australia, 2020
27 GMDS-II Neurodevelopment 93 (85–100)E Normal
18 Gischler22
Netherlands, 2009
13 BSID-I Motor 99.2 (83.0–115.4)A Normal
Cognition 99.6 (87.5–111.6)
Cognition 93 (78–113)

BOS, Bayley Ontwikkelings Schalen (Dutch version of BSID-I); BSID, Bayley Scales of Infant and Toddler Development; CAT/CLAMS, Capute Scale Clinical Adaptive Test/Clinical Auditory Milestone Scale; GMDS, Griffiths Mental Development Scales; US, United States.

AMean (95% confidence interval).

BMean ± standard deviation.

CMean (range).

DMean.

EMedian (IQR).

Table 4.

Neurodevelopmental outcome in school-aged children (≥6 years old) born with esophageal atresia

Age (year) Author, year No. of patients ( n ) Test method Outcome measure Test result Conclusion
6 Giúdici23
Argentina, 2016
10 PRUNAPE Fine and gross motor function, language skills and social area Normal in n = 3 (30%) Significantly lower than normal
7 (3–12)A König28
Germany, 2018
12 KTT/DMT Motor 2.19B Impaired compared with controls (P = 0.04) and norm values (P = 0.00)
8 Harmsen24
Netherlands, 2017
49 M-ABC & M-ABC-II Motor z-score − 0.53 ± 0.91C Impaired (P < 0.001)
46 WISC-III-NL & RAKIT Full-scale IQ
Total verbal IQ
Total performance IQ
102 ± 14C
103 ± 14C
98 ± 14C
Normal
6–17D Kubota29
Japan, 2011
20 WISC-III & KSPD Cognition IQ < 70 in n = 5 (25%) Higher incidence of mental retardation compared with the reference population (2–3%).
6–16D Bakal20
Turkey, 2016
15 WISC-R Cognition IQ 95–110E Normal
10.2 (8–12)E Bouman27
Netherlands, 1999
36 WISC-RN Cognition IQ 90.2 ± 16C Impaired (P < 0.01)

KTT/DMT, Kinderturntest Plus/Deutscher Motorik Test; KSPD, Kyoto Scale of Psychological Development; M-ABC, Movement-Assessment Battery for Children; PRUNAPE, Prueba Nacional de Pesquisa (Argentine Screening Test); RAKIT, Revised Amsterdam Intelligence Test; US, United States; WISC, Wechsler Intelligence Scale for Children.

AMedian (range).

BMean.

CMean ± SD.

DRange.

EMean (range).

Characteristics of the included studies are summarized in Table 1. Risk of bias was present in all studies (Table 5). None of the studies had performed a sample size calculation. One study was retrospective, whereas all others were prospective studies that included patients in consecutive order.

Table 5.

Risk of bias analysis MINORS

Study A clearly stated aim Inclusion of consecutive patients Prospective collection of data Endpoint appropriate to the aim of the study Unbiased assessment of the study endpoint Follow-up period appropriate to the aim of the study Loss to follow-up less than 5% Prospective calculation of the study size An adequate control group Contemporary groups Baseline equivalence of groups Adequate statistical analysis Total
Bouman27 2 2 2 2 2 2 NR 0 NR NR NR NR 12/24
Francesca34 2 2 2 2 2 2 0 0 0 NR NR 2 14/24
Gischler22 2 2 2 2 2 2 2 0 NR NR NR NR 14/24
Walker 201335 2 2 2 2 2 2 NR 0 2 2 2 2 20/24
Faugli36 2 2 2 2 2 2 NR 0 NR NR NR 2 14/24
Costerus21 2 2 2 2 2 2 2 0 NR NR NR NR 14/24
Giudici23 1 2 2 2 2 2 0 0 NR NR NR NR 11/24
Walker 201626 2 2 2 2 2 2 1 0 2 2 2 2 21/24
Mawlana17 2 2 2 2 2 2 NR 0 NR NR NR NR 12/24
Konig28 2 2 2 2 2 2 1 0 2 NR 2 2 19/24
van der Cammen25 2 2 2 2 2 2 NR 0 NR NR NR NR 12/24
Harmsen24 2 2 2 2 2 2 1 0 NR NR NR NR 13/24
Bakal20 2 2 2 2 2 2 NR 0 NR NR NR NR 12/24
Kubota29 2 2 2 2 2 2 NR 0 NR NR NR NR 12/24
Batta37 2 2 0 2 2 2 0 0 2 NR NR 2 14/24

NR, not reported.

Infants (<2 years old)

Six studies evaluated neurodevelopmental outcome in children under 2 years old (Table 2 and Fig. 2). One study used BSID-I, one study used BSID-II, and two studies used the Bayley-3. The BSID-I and the BSID-II contain two domains (motor and cognitive functioning), whereas the Bayley-3 also contains a domain on language skills. The other studies used the CAT/CLAMS (Capute Scale Clinical Adaptive Test/Clinical Auditory Milestone Scale) and the GMDS-II (Griffiths Mental Development Scales-II).

At 6 months of age, normal neurodevelopment was found in two longitudinal cohort studies: Gischler et al. (BSID-I, ages 6, 12, 18, and 24 months, n = 13)22 and Francesca et al. (Bayley-3, ages 6 and 12 months, n = 82).34 At 12 months of age, both these studies again found normal motor and cognitive functioning.22,34 Francesca et al. found a delay with time. They found a significantly lower median motor score at 12 months, compared with the score at 6 months old (P = 0.033), but higher cognitive function at 12 months compared with the score at 6 months (P = 0.000). Gischler et al. found no differences at 12 months compared with the scores of the same cohort at age 6 months, and results at age 18 months also showed normal motor and cognitive functioning.22

One other study that administered the Bayley-3 at 12 months of age found normal motor, cognitive and receptive language functions but a significantly impaired expressive language functioning (n = 31, P < 0.05).35 A study using the BSID-II reported a normal neurodevelopment (n = 36).36 A retrospective study using the GMDS-II at age 12 months (n = 27) found normal neurodevelopment.37

A longitudinal study from Argentina (CAT/CLAMS, ages 1, 2, and 6 years, n = 23) found an abnormally low neurologic-psychomotor developmental index (NPDI) in five (24%) children at 1 year of age.23

In summary, most studies in infants show normal neurodevelopment compared with healthy controls, whereas only one study found impaired expressive language functioning at 12 months of age.35

Preschoolers (2–5 years old)

Eight studies assessed children’s neurodevelopment at preschool age (Table 3 and Fig. 2). Full-range neurodevelopment was assessed in five studies; two used the BSID-I or -II17,21; two used the Bayley-322,26; and one the CAT/CLAMS.23 One study measured cognitive functioning with the Ankara developmental screening inventory (ADSI), a validated Turkish instrument, to measure cognitive functioning.20 Motor functioning was assessed with the M-ABC in two studies.24,25

Table 3.

Neurodevelopmental outcome in preschoolers (2–5 years old) born with esophageal atresia

Age (months) (Year) Author, year No. of patients ( n ) Test method Outcome measure Test result Conclusion
2 Gischler22
Netherlands, 2009
13 BSID-I Motor
Cognition
94.8 (75.9–113.7)A
95.4 (80.0–110.8)
Normal
2 Costerus21
Netherlands, 2019
5 BSID-II-NL Motor
Cognition
87 (83–96)B
93 (78–113)
Normal
24 ± 9C Mawlana17
Canada, 2018
182 Bayley-3 Motor
Cognition
Language
Delay >1 SD n = 32 (18%)
Delay >1 SD n = 44 (24%)
Delay >1 SD n = 40 (22%)
Significantly lower than normal
3 Walker26
Australia, 2016
24 Bayley-3 Fine motor
Gross motor
Cognition
Receptive language
Expressive language
10.96D
9.25
9.71
11.42
10.67
Receptive language improved (P < 0.001), other scales normal
3 Giúdici23
Argentina, 2016
14 CAT/CLAMS Visomotor & receptive and expressive language skills Normal in n = 7 (50%) Significantly lower than normal
5 Harmsen24
Netherlands, 2017
54 M-ABC &
M-ABC-II
Motor z-score − 0.75 ± 0.83E Impaired (P < 0.001)
5.9 ± 0.5A Van der Cammen-van Zijp25
Netherlands, 2010
29 M-ABC Total impairment score
Manual Dexterity
Ball skills
Balance skills
Impaired P ≤ 15 n = 10 (34%)
Impaired P < ≤5 n = 2 (7%)
Impaired P ≤ 15 n = 14 (48%)
Impaired P ≤ 15 n = 12 (41%)
Total impairment score (P < 0.05), ball skills (P < 0.01) and balance skills (<0.01) impaired, manual dexterity normal
0–6C Bakal20
Turkey, 2016
24 ADSI Cognition Normal in all (100%) Normal

ADSI, Ankara Developmental Screening Inventory; BSID, Bayley Scales of Infant and Toddler Development; CAT/CLAMS, Capute Scale Clinical Adaptive Test/Clinical Auditory Milestone Scale; M-ABC, Movement-Assessment Battery for Children; US, United States.

AMean (95% confidence interval).

BMedian (range).

CMean ± SD.

DMean.

ERange.

Within the framework of a structured longitudinal follow-up program, Gischler et al. (BSID-I, ages 6, 12, 18, and 24 months, n = 13) showed normal motor and cognitive functioning at age 24 months.22 Costerus et al. (BSID-II, age 2 years, n = 5) found normal outcome scores, although one child, diagnosed with Feingold syndrome, showed delayed cognitive functioning and one other child slightly delayed motor function.21

A retrospective study in Canadian children (Bayley-3, age 24 months, n = 182) found a significant delay of >1 SD for all domains of the Bayley-3.17 During the first period of this study, children were only assessed if the result of the ASQ—a validated screening instrument for communication, gross motor, fine motor, problem solving, and personal–social skills—had raised concerns.38 During the remaining study period, each child was standardly assessed with the Bayley-3. Another cross-sectional study from a Turkish group (ADSI, age 0–6 years, n = 24) found intellectual levels in accordance with the children’s age.20

The children in the Australian study who had been tested at the age of 1 year,35 showed at 3 years of age no significant differences in all subdomains of the Bayley-3, but significantly improved receptive language skills (P = 0.001, Bayley-3, age 3 years, n = 24).26 The Argentinian group (CAT/CLAMS, ages 1, 2, and 6 years, n = 14) found abnormal NPDI in 7 out of 14 (50%) children.23

Two studies—with partly the same cohort—appraised the motor function of 5-year-old children with the use of the M-ABC, within the framework of a structured longitudinal follow-up program. Van der Cammen-van Zijp et al. (M-ABC, age 5.9 years, n = 29, cohort born 1999– 2003) found a significantly lower total impairment score (P < 0.05), ball skills, and balance skills (P < 0.01), whereas manual dexterity was within normal ranges, compared with Dutch reference values.25 Harmsen et al. (M-ABC and M-ABC II, ages 5 and 8 years, n = 54, cohort born 1999–2006) showed a significantly (P < 0.001) reduced motor function at 5 years, characterized by impaired gross motor skills, although fine motor skills were not impaired.24

In summary, preschoolers show impaired neurodevelopment in 2/5 studies,17,23 normal cognitive performance in 1/1 study,20 and impaired motor function in 2/2 studies.24,25

School-aged children (≥6 years old)

Six studies assessed the neurodevelopment of children aged 6 years or older (Table 4 and Fig. 2). One study assessed the full-range neurodevelopment using the Prueba Nacional de Pesquisa (PRUNAPE, Argentine Screening Test).23 Cognitive performance was assessed in four studies with the WISC,20,24,27,29 and in one of these additionally with the Revised Amsterdam Intelligence Test (RAKIT).24 The two other studies assessed motor functioning; one with the M-ABC24 and the other with the Kinderturntest Plus/Deutscher Motorik Test (KTT/DMT).28

The Argentinian study group (CAT/CLAMS, ages 1, 2, and 6 years, n = 10) found borderline or impaired neurodevelopment in seven patients (70%). Four out of the seven patients with a normal NPDI at age 1 year had abnormal rest results at age 6 years (McNemar’s test, P = 0.04).23

Four studies evaluated cognitive performance with the WISC in school-aged children. Kubota et al. (WISC-III & KSPD, age 6–17 years, n = 20) showed that five of the children (25%) had IQ-scores < 70, defined as intellectual disability, which proportion was significantly higher than the 2–3% incidence in the general Japanese population.29 Bakal et al. (WISC-R, age 6–16 years, n = 15) found IQ levels within normal range (range 95–110).20 Bouman et al. (WISC-RN, age 10.2 years, n = 36) found a 10-points lower IQ (90.2 vs. 100, P < 0.01) than Dutch reference norms (P < 0.01).27 The prospective study of Harmsen et al. (WISC-III-NL & RAKIT, age 8 years, n = 46) found normal IQ levels (P = 0.26).24 This study also assessed motor function (M-ABC and M-ABC II, ages 5 and 8 years, n = 49); the mean M-ABC z-score was significantly lower than normative values (P < 0.001), and did not improve significantly from age 5 years to 8 years (linear mixed model, z-score + 0.24, P = 0.074).24

A German cross-sectional study (KTT/DMT, age 7 years, n = 17) assessed motor functioning. The children born with EA scored significantly lower than both age-matched healthy controls and the reference population.28

In summary, school-aged children show impaired neurodevelopment in 1/1 study,23 impaired cognitive performance in 2/4 studies,27,29 and impaired motor function in 2/2 studies compared with healthy controls.24,28

Associations with neurodevelopment

In total, five studies reported statistical data on the association between covariables and neurodevelopment. Gischler et al. used random regression modelling, which revealed that a higher number of congenital anomalies, higher severity of illness during admission, the higher number of surgical interventions in the first 24 months, and additional medical problems (e.g. O2 or tracheostomy at home) were associated with an impaired motor and cognitive functioning (all P < 0.05). Length of stay in the first 6 months was negatively associated with motor functioning as well (P < 0.05).22 With multivariate regression, Francesca et al. found birth weight to be positively associated with motor function at 6 months of age, whereas length of stay and weight at 12 months beneath the 5th percentile were both negatively associated with motor function at 12 months.34

The total number of major congenital anomalies correlated negatively with motor functioning (Spearman, P = 0.007) in the study of van der Cammen-van Zijp et al. They also found a significant negative correlation with duration of hospitalization (P = 0.003) and number of surgical interventions (P = 0006).25 Furthermore, a longitudinal linear mixed model analysis of Harmsen et al revealed that duration of anesthetic exposure within the first 24 months was negatively associated with motor functioning (P = 0.018). Sports participation was positively associated with motor functioning at 8 years (P = 0.002).24 The study of Batta et al found that birthweight and length of stay in the hospital were associated with neurodevelopment at 1 year of age.37

DISCUSSION

We conducted this systematic review to provide an overview on the current knowledge on the long-term neurodevelopmental outcome—including both motor function and cognitive performance—of children born with EA. Most studies found cognitive performance comparable with the reference population (Fig. 2A) and motor function below normal (Fig. 2B). Two of the six studies in infants found developmental problems; i.e. impaired expressive language and impaired overall neurodevelopment, respectively. Regarding preschoolers, five of eight studies found developmental problems. One of these found receptive language to be improved, two found overall neurodevelopment to be impaired, and two found motor function to be impaired. Regarding school-aged children, five of six studies found developmental problems, three in overall neurodevelopment and two in motor function.

Heterogeneity of included studies

The overview provided by this systematic review highlights the heterogeneity of the published data on the neurodevelopmental outcome of children with EA. Unfortunately, various studies only report a dichotomous outcome, without detailed results.17,20,23,25,29,39 Moreover, both the data and the reference values differ between studies which complicates drawing conclusions on neurodevelopment over time. Therefore, given the wide variety in tests, ages, and sample sizes, a meta-analysis could not be performed.

Interpretation of the results

Infants (0–2 years): Up to 12 months of age, both cognitive and motor functioning were within normal limits in most studies, and only one study found an impairment for expressive language.35 This would indicate that infants do not suffer neurodevelopmental impairments. More problems were revealed, however, at older ages.

Preschoolers (2–5 years): In preschoolers, two neurodevelopmental studies found cognitive impairments.17,23 Both motor function studies found mild motor problems and two out of five studies that assessed neurodevelopment also found motor function impairments.17,23–25 This would indicate that preschoolers start showing neurodevelopmental impairments, more than found in studies performed in infants.

School-aged children (6–18 years): Two out of four cognitive studies found an impaired cognitive performance with lower IQ levels.27,29 Both studies assessing motor function found an impaired motor functioning.24,28 In addition, one neurodevelopment study found motor impairment.23 This would indicate that the eldest studied patients suffer the most neurodevelopmental impairments of all assessed subgroups.

A study analyzing change over time, found unchanged impaired motor function at ages 5 and 8 years.24 Sports participation was reported for 8-year-old children only, and correlated positively with motor function at that age.

Giúdici et al reported a significant decrease in the number of patients with a normal NPDI with increasing age.23 However, the NPDI had been assessed with the CAT/CLAMS at ages 1 and 3 years, and with the PRUNAPE at age 6 years. The results should therefore be interpreted with caution. Since 11 out of the 21 children in that study were lost to follow-up and characteristics of those children were not reported, an inclusion bias cannot be ruled out. Lastly, although described in two separate papers, Walker et al evaluated the same study population at ages 1 and 3 years and found impaired expressive language at age 1 year and improved receptive language at age 3 years.26,35

Causes of neurodevelopmental impairments

Neurodevelopment has already been studied in critically ill children and children born with other anatomical malformations than EA. Neurodevelopmental impairments have been reported in children who received ECMO treatment and children who received ECMO treatment after surgery for congenital diaphragmatic hernia.7,8 The systematic review on ECMO treatment also struggled with the heterogeneity of the included studies, but their results suggested a wide range of disabilities.7

There is an ongoing discussion on the cause of impaired neurodevelopment in children born with a congenital malformation. Previous research in anesthesia showed that this impairment might be associated with various intraoperative surgical and anesthesiologic events.40 Ventilator time and repeated exposure to anesthesia have been associated with impaired long-term neurodevelopmental outcome.41 Repeated exposure is of increased importance in patients undergoing complex surgeries and surgical complications.24,42,43 Animal studies showed a clear relationship between anesthetic dose and duration of anesthesia and impaired development, but doses administered in animals are not comparable with doses administered in human populations.44 However, the potential neurotoxic effect of anesthetics is less clear in clinical studies. A review found only little evidence for the risk of adverse developmental outcome after neonatal surgery.45 Potentially, the harmfulness of anesthetic exposure is determined by the combination of the type of anesthesia, the duration of exposure, the child’s age, and the effects of anesthetics on the perfusion of the brain, but future research is required to explore this hypothesis. Another hypothesis has it that impaired neurodevelopment is inherent to the congenital malformation.

Furthermore, it has been hypothesized that after neonatal critical illness the hippocampus is affected by a combination of factors including hypoxia, neuroinflammation, (surgical) stress, and exposure to anaesthetics.46 Comparative studies on this issue can gain more insight in the potential causes of long-term developmental impairment in all patient groups, and in ways to stimulate cognitive development.47

The results from the present review show that children born with EA are at risk for impaired neurodevelopmental outcome as well as for impaired cognitive and motor development. A structured, longitudinal follow-up program focused on motoric and neurodevelopment run by a multidisciplinary team may help to solve uncertainties for the parents and to offer timely intervention, for instance physiotherapy, when necessary. If there is indeed a developmental problem in this population, longitudinal studies with standardized follow-up at various ages could be helpful to reveal potential causes and give insight in the effects of interventions.48

Strengths, limitations, and recommendations

To our knowledge, this is the first systematic review addressing neurodevelopmental outcome in children with EA. One of the strengths is the thorough search strategy. Also, the wide age spread gives an overview of the neurodevelopment during multiple stages of a child’s life. However, several limitations need to be addressed. First, although the quality of each included study seems good (Table 5), a broad range of tests were used to assess neurodevelopment, including national instruments such as the PRUNAPE, ADSI, RAKIT, and KSPD. Nevertheless, these instruments have all been validated, and test results were compared with local reference norms.49–52 In some cases, different versions of an instrument sometimes assessed slightly different developmental skills. For example, the cognitive scale of the BSID-II included more linguistic skills than the Bayley-3. This variety in tests complicates the comparison between studies.

Secondly, selection bias could have affected results. An example is the retrospective chart review of Mawlana et al, in which during an unspecified part of the study period the Bayley-3 was assessed only if the ASQ was abnormal.17 Nevertheless, we have decided to include this study because of its large sample size. Moreover, data on non-participants, which could have influenced the outcomes of the tested cohorts for better or for worse, were missing in all studies but one. Only Harmsen et al disclosed background information about the non-participants.24 Furthermore, referral bias may have occurred in that parents of children without problems may have not to participate in follow-up programs. Overall, inclusion criteria varied among studies. Four studies clearly stated to have excluded patients with syndromal or chromosomal abnormalities, neurological impairment, or intellectual disability,22,24,25,37 whereas others did not. For example, the cohort of Giúdici et al contained one patient with trisomy 21, one with Edwards syndrome and two with cerebral palsy.23

Our search did not identify studies that used validated questionnaires to assess the neurodevelopment of patients born with EA. This type of studies could be of additional value to the studies discussed in this systematic review, which all used validated physical assessment tools to assess the neurodevelopment.

The present study highlights the potential neurodevelopmental impairments of these children. International standardization of testing protocols is advocated.53 Recommendations would include testing with the instruments and reporting more detailed data, for instance using standard deviation and/or z-scores. This would facilitate meta-analyses and drawing accurate conclusions.

CONCLUSION

In conclusion, this systematic review shows that impairments were mostly found in motor function, but also in cognitive performance. In general, the findings of this review raise concerns regarding the long-term outcome of children after congenital EA surgery. Participation in a structured long-term follow-up program for this patient population is recommended, because this allows timely detection and treatment of neurodevelopmental problems.

ACKNOWLEDGMENTS

We thank Ko Hagoort of the Erasmus MC-Sophia Children’s Hospital, Rotterdam for editorial assistance and Wichor M. Bramer, Biomedical Information Specialist, Medical Library, Erasmus MC–Erasmus University Medical Centre, Rotterdam for helping to construct the search strategy.

Contributor Information

Camille E van Hoorn, Department of Anaesthesiology, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands; Department of Paediatric Surgery, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

Chantal A ten Kate, Department of Paediatric Surgery, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

Andre B Rietman, Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands, and.

Leontien C C Toussaint-Duyster, Department of Orthopaedics, Section of Physical Therapy, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

Robert Jan Stolker, Department of Anaesthesiology, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

Rene M H Wijnen, Department of Paediatric Surgery, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

Jurgen C de Graaff, Department of Anaesthesiology, Erasmus MC-Sophia Children’s Hospital University Medical Centre, Rotterdam, The Netherlands.

ETHICAL APPROVAL

Not applicable.

DISCLOSURES

None.

FUNDING

Departmental sources.

CONFLICT OF INTEREST

No conflicts of interest declared.

PRIOR PRESENTATION OF STUDY DATA

Not applicable.

References

  • 1. Pedersen R N, Calzolari E, Husby S, Garne E. Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies in 23 European regions. Arch Dis Child 2012; 97(3): 227–32. [DOI] [PubMed] [Google Scholar]
  • 2. Sulkowski J P, Cooper J N, Lopez J Jet al. Morbidity and mortality in patients with esophageal atresia. Surgery 2014; 156(2): 483–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Kovesi T. Long-term respiratory complications of congenital esophageal atresia with or without tracheoesophageal fistula: an update. Dis Esophagus 2013; 26(4): 413–6. [DOI] [PubMed] [Google Scholar]
  • 4. Toussaint-Duyster L C C, Zijp M H M, Spoel Met al. Determinants of exercise capacity in school-aged esophageal atresia patients. Pediatr Pulmonol 2017; 52(9): 1198–205. [DOI] [PubMed] [Google Scholar]
  • 5. Connor M J, Springford L R, Kapetanakis V V, Giuliani S. Esophageal atresia and transitional care--step 1: a systematic review and meta-analysis of the literature to define the prevalence of chronic long-term problems. Am J Surg 2015; 209(4): 747–59. [DOI] [PubMed] [Google Scholar]
  • 6. Dellenmark-Blom M, Quitmann J, Dingemann C. Health-related quality of life in patients after repair of Esophageal atresia: a review of current literature. Eur J Pediatr Surg 2020; 30(3): 239–50. [DOI] [PubMed] [Google Scholar]
  • 7. Boyle K, Felling R, Yiu A, Battarjee W, Schwartz J M E, Salorio C, Bembea M M. Neurologic outcomes after extracorporeal membrane oxygenation: a systematic review. Pediatr Crit Care Med 2018; 19(8): 760–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Madderom M J, Toussaint L, Zijp M Het al. Congenital diaphragmatic hernia with(out) ECMO: impaired development at 8 years. Arch Dis Child Fetal Neonatal Ed 2013; 98(4): F316–22. [DOI] [PubMed] [Google Scholar]
  • 9. Hoorn C E, Costerus S A, Lau J, Wijnen R M H, Vlot J, Tibboel D, Graaff J C. Perioperative management of esophageal atresia/tracheo-esophageal fistula: an analysis of data of 101 consecutive patients. Paediatr Anaesth 2019; 29(10): 1024–32. [DOI] [PubMed] [Google Scholar]
  • 10. Hoorn C E, Cammen-van Zijp M H M, Stolker R J, Rosmalen J, Wijnen R M H, Graaff J C, Vutskits L. Associations of perioperative characteristics with motor function in preschool children born with esophageal atresia. Paediatr Anaesth 2021; 31(8): 854–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Diamond A. Interrelated and interdependent. Dev Sci 2007; 10(1): 152–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Moher D, Liberati A, Tetzlaff J, Altman D G, Group P . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62(10): 1006–12. [DOI] [PubMed] [Google Scholar]
  • 13. Bramer W M, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using EndNote. J Med Libr Assoc 2017; 105(1): 84–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Bramer W M, Giustini D, Jonge G B, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc 2016; 104(3): 240–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Williams K, Thomson D, Seto Iet al. Standard 6: age groups for pediatric trials. Pediatrics 2012; 129(Suppl 3): S153–60. [DOI] [PubMed] [Google Scholar]
  • 16. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003; 73(9): 712–6. [DOI] [PubMed] [Google Scholar]
  • 17. Mawlana W, Zamiara P, Lane H, Marcon M, Lapidus-Krol E, Chiu P P L, Moore A M. Neurodevelopmental outcomes of infants with esophageal atresia and tracheoesophageal fistula. J Pediatr Surg 2018; 53(9): 1651–4. [DOI] [PubMed] [Google Scholar]
  • 18. Bevilacqua F, Ravà L, Valfrè Let al. Factors affecting short-term neurodevelopmental outcome in children operated on for major congenital anomalies. J Pediatr Surg 2015; 50(7): 1125–9. [DOI] [PubMed] [Google Scholar]
  • 19. Aite L, Bevilacqua F, Zaccara Aet al. Short-term neurodevelopmental outcome of babies operated on for low-risk esophageal atresia: a pilot study. Dis Esophagus 2014; 27(4): 330–4. [DOI] [PubMed] [Google Scholar]
  • 20. Bakal U, Ersoz F, Eker I, Sarac M, Aydin M, Kazez A. Long-term prognosis of patients with Esophageal atresia and/or tracheoesophageal fistula. Indian J Pediatr 2016; 83(5): 401–4. [DOI] [PubMed] [Google Scholar]
  • 21. Costerus S, Vlot J, Rosmalen J, Wijnen R, Weber F. Effects of neonatal Thoracoscopic surgery on tissue oxygenation: a pilot study on (neuro-) monitoring and outcomes. Eur J Pediatr Surg 2019; 29(2): 166–72. [DOI] [PubMed] [Google Scholar]
  • 22. Gischler S J, Mazer P, Duivenvoorden H J, van Dijk M, Bax N M A, Hazebroek F W J, Tibboel D. Interdisciplinary structural follow-up of surgical newborns: a prospective evaluation. J Pediatr Surg 2009; 44(7): 1382–9. [DOI] [PubMed] [Google Scholar]
  • 23. Giudici L B, Bokser V S, Golombek S G, Castrillon C C, Trovato M, Ferrario C C. Esophageal atresia: long-term interdisciplinary follow-up. J Pediatr Neonatal Individ Med 2016; 5(2). [Google Scholar]
  • 24. Harmsen W J, Aarsen F J, Van Der Cammen-Van Zijp M H Met al. Developmental problems in patients with oesophageal atresia: a longitudinal follow-up study. Arch Dis Child Fetal Neonatal Ed 2017; 102(3): F214–F9. [DOI] [PubMed] [Google Scholar]
  • 25. Zijp M H M, Gischler S J, Mazer P, Dijk M, Tibboel D. H IJ. Motor-function and exercise capacity in children with major anatomical congenital anomalies: an evaluation at 5 years of age. Early Hum Dev 2010; 86(8): 523–8. [DOI] [PubMed] [Google Scholar]
  • 26. Walker K, Loughran-Fowlds A, Halliday R, Badawi N, Stewart J, Holland A J A. Developmental outcomes at three years of age of infants with esophageal atresia. J Pediatr Surg 2016; 51(2): 249–51. [DOI] [PubMed] [Google Scholar]
  • 27. Bouman N H, Koot H M, Hazebroek F W J. Long-term physical, psychological, and social functioning of children with esophageal atresia. J Pediatr Surg 1999; 34(3): 399–404. [DOI] [PubMed] [Google Scholar]
  • 28. Konig T T, Muensterer O J. Physical fitness and locomotor skills in children with Esophageal atresia-a case control pilot study. Front Pediatr 2018; 6: 337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Kubota A, Nose K, Yamamoto Eet al. Psychosocial and cognitive consequences of major neonatal surgery. J Pediatr Surg 2011; 46(12): 2250–3. [DOI] [PubMed] [Google Scholar]
  • 30. Bayley N. Bayley Scales of Infant and Toddler Development, 3rd edn. San Antonio, TX: Harcourt Assessment Journal of Psychoeducational Assessment; 2006; 25(2): 180-90. [Google Scholar]
  • 31. Hendersen S E, Sugden D A, Barnett A. Movement Assessment Battery for Children-Second edition. Dutch Manual. Amsterdam: Pearson, 2010. [Google Scholar]
  • 32. Schoemaker M M, Niemeijer A S, Flapper B C, Smits-Engelsman B C. Validity and reliability of the movement assessment battery for children-2 checklist for children with and without motor impairments. Dev Med Child Neurol 2012; 54(4): 368–75. [DOI] [PubMed] [Google Scholar]
  • 33. Tulsky D S, Saklofske D H, Wilkins C, Weiss L G. Development of a general ability index for the Wechsler adult intelligence scale--third edition. Psychol Assess 2001; 13(4): 566–71. [DOI] [PubMed] [Google Scholar]
  • 34. Francesca B, Benedetta R, Andrea Cet al. Neurodevelopmental outcome in infants with esophageal atresia: risk factors in the first year of life. Dis Esophagus 2021; 34(5). [DOI] [PubMed] [Google Scholar]
  • 35. Walker K, Halliday R, Badawi N, Stewart J, Holland A J A. Early developmental outcome following surgery for oesophageal atresia. J Paediatr Child Health 2013; 49(6): 467–70. [DOI] [PubMed] [Google Scholar]
  • 36. Faugli A, Emblem R, Bjørnland K, Diseth T H. Mental health in infants with esophageal atresia. Infant Ment Health J 2009; 30(1): 40–56. [DOI] [PubMed] [Google Scholar]
  • 37. Batta V, Rao S, Wagh Det al. Early neurodevelopmental outcomes of congenital gastrointestinal surgical conditions: a single-centre retrospective study. BMJ Paediatr Open 2020; 4(1): e000736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Schonhaut L, Armijo I, Schönstedt M, Alvarez J, Cordero M. Validity of the ages and stages questionnaires in term and preterm infants. Pediatrics 2013; 131(5): e1468–74. [DOI] [PubMed] [Google Scholar]
  • 39. Nomura A, Yamoto M, Fukumoto Ket al. Evaluation of developmental prognosis for esophageal atresia with tracheoesophageal fistula. Pediatr Surg Int 2017; 33(10): 1091–5. [DOI] [PubMed] [Google Scholar]
  • 40. McCann M E, Soriano S G. Does general anesthesia affect neurodevelopment in infants and children? BMJ 2019; 367: l6459. [DOI] [PubMed] [Google Scholar]
  • 41. Peters R T, Ragab H, Columb M O, Bruce J, MacKinnon R J, Craigie R J. Mortality and morbidity in oesophageal atresia. Pediatr Surg Int 2017; 33(9): 989–94. [DOI] [PubMed] [Google Scholar]
  • 42. Fiser D H, Tilford J M, Roberson P K. Relationship of illness severity and length of stay to functional outcomes in the pediatric intensive care unit: a multi-institutional study. Crit Care Med 2000; 28(4): 1173–9. [DOI] [PubMed] [Google Scholar]
  • 43. Zaccariello M J, Frank R D, Lee Met al. Patterns of neuropsychological changes after general anaesthesia in young children: secondary analysis of the Mayo Anesthesia Safety in Kids study. Br J Anaesth 2019; 122(5): 671–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Lasarzik I, Noppens R R, Wolf Tet al. Dose-dependent influence of sevoflurane anesthesia on neuronal survival and cognitive outcome after transient forebrain ischemia in Sprague-Dawley rats. Neurocrit Care 2011; 15(3): 577–84. [DOI] [PubMed] [Google Scholar]
  • 45. Davidson A J, Sun L S. Clinical evidence for any effect of Anesthesia on the developing brain. Anesthesiology 2018; 128(4): 840–53. [DOI] [PubMed] [Google Scholar]
  • 46. Schiller R, IJsselstijn H, Hoskote Aet al. Memory deficits following neonatal critical illness: a common neurodevelopmental pathway. Lancet Child Adolesc Health 2018; 2(4): 281–9. [DOI] [PubMed] [Google Scholar]
  • 47. Schiller R M, IJsselstijn H, Madderom M Jet al. Training-induced white matter microstructure changes in survivors of neonatal critical illness: a randomized controlled trial. Dev Cogn Neurosci 2019; 38: 100678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Pearson D A, Aman M G, Arnold L Eet al. High concordance of parent and teacher attention-deficit/hyperactivity disorder ratings in medicated and unmedicated children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2012; 22(4): 284–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Sezgin N. Two different validity study of Ankara developmental screening inventory (ADSI): criterion-related validity and concurrent discrimination validity. Turk J Child Adolesc Ment Health 2011; 33: 18–27. [Google Scholar]
  • 50. Lejarraga H, Menéndez A M, Menzano Eet al. PRUNAPE: screening for psychomotor development problems at primary care level. Arch Argent Pediatr 2008; 106(2): 119–25. [DOI] [PubMed] [Google Scholar]
  • 51. Bleichrodt N, Zaal J, Resing W. Revision Amsterdam Child Intelligence Test: Manual. Amsterdam: Pearson, 1984. [Google Scholar]
  • 52. Ikuzawa M, Matsushita Y, Nakase A. Kyoto Scale of Psychological Development 2001. Kyoto: Kyoto International Social Welfare Exchange Centre, 2002. [Google Scholar]
  • 53. Dingemann C, Eaton S, Aksnes Get al. ERNICA consensus conference on the management of patients with esophageal atresia and tracheoesophageal fistula: follow-up and framework. Eur J Pediatr Surg 2020; 30(6): 475–82. [DOI] [PubMed] [Google Scholar]
  • 54. Gross R E. The Surgery of Infancy and Childhood: Its Principles and Techniques. Philadephia and London: WB Saunders, 1953. [Google Scholar]
  • 55. Solomon B D. VACTERL/VATER Association. Orphanet J Rare Dis 2011; 6(1): 56. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Diseases of the Esophagus are provided here courtesy of Oxford University Press

RESOURCES